Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dedicator of cytokinesis protein 7 (DOCK7) is an atypical guanine nucleotide exchange factor that activates Rac1 and Rac3 GTPases by facilitating GDP-GTP exchange, distinct from canonical GEFs by its DHR2 domain. It plays critical roles in neuronal development—including axon formation and polarization, radial glial cell fate, and signal transduction—and is essential for normal muscle fusion and regeneration via cytoskeletal rearrangement. Pathogenic variants of DOCK7 cause severe neurodevelopmental disorders such as developmental and epileptic encephalopathy 23, with manifestations including epilepsy, intellectual disability, muscle hypotonia, and cortical blindness. DOCK7 is viewed as a high-potential therapeutic target, especially for conditions with impaired Rac1 pathway activation or cytoskeletal dysfunction.
Small molecules could inhibit or modulate DOCK7’s GEF activity, blocking Rac1/Rac3 activation; PI3K pathway modulation may affect Dock7 recruitment and downstream effects.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dedicator of cytokinesis protein 7 (DOCK7).